Diatrizoate
Brand names: Gastrografin · Active ingredient: Diatrizoate Meglumine, Diatrizoate Sodium
In short: Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfa
What is Diatrizoate used for?
Gastrografin (Diatrizoate Meglumine and
Diatrizoate Sodium Solution) is indicated for radiographic examination
of segments of the gastrointestinal tract (esophagus, stomach, proximal
small intestine, and colon). The preparation is particularly indicated
when a more viscous agent such as barium sulfate, which is not water-soluble,
is not feasible or is potentially dangerous.
Gastrografin may also be used as an adjunct to contrast
enhancement in computed tomography of the torso (body imaging); the
preparation is indicated, in conjunction with intravenous administration
of a radiopaque contrast agent, when unenhanced imaging may not provide
sufficient definition in distinguishing normal loops of bowel from
adjacent organs or areas of suspected pathology.
âš Boxed warning (FDA's strongest warning)
Dehydration: Administration of hypertonic
Gastrografin solutions may lead to hypovolemia and hypotension due
to fluid loss from the intestine. A 1 in 4.6 (1:4.6) dilution of Gastrografin
yields an approximately isotonic 16.5 percent diatrizoate salts solution;
less dilute solutions are hypertonic and may lead to intraluminal
movement of fluid with resulting hypovolemia. In young or debilitated
children and in elderly cachectic persons, the loss of plasma fluid
may be sufficient to cause a shock-like state. If Gastrografin is
used in infants and children (under 10 kg) or in dehydrated or debilitated
patients, the solution must be prepared using the specific dilutions
described in DOSAGE AND ADMINISTRATION. In
debilitated patients and in patients with electrolyte imbalances,
postprocedural monitoring of hydration, serum osmolarity, electrolytes
and clinical status is essential. In pediatric or severely debilitated
patients, the maintenance of an open intravenous fluid line for rehydration
may be advisable should hypotension or shock supervene. Electrolyte
disturbances must be corrected prior to the administration of any
hypertonic Gastrografin solutions.
Aspiration: Aspiration of Gastrografin into the trachea and airways
may result in serious pulmonary complications including, pulmonary
edema, pneumonitis or death Bronchial entry of any orally administered
contrast medium causes a copious osmotic effusion. Therefore, avoid
use of Gastrografin in patients with esophagotracheal fistula and
minimize risks for pulmonary aspiration in all patients. …
Diatrizoate dosage
This medium is not to be used for
the preparation of solutions for parenteral administration. Oral or
rectal administration only. Discard any unused portion after procedure.
The routine preparatory measures
employed for barium studies are also appropriate for this agent.
For pediatric and severely cachectic patients
the maintenance of an intravenous fluid line may be advisable.
Oral Administration: Adult oral dosage
may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature
of the examination and the size of the patient. For infants and children
less than 5 years of age, 30 mL (11 g iodine) are usually adequate;
for children 5 to 10 years of age, the suggested dose is 60 mL (22
g iodine). These pediatric doses may be diluted 1:1, if desired, with
water, carbonated beverage, milk, or mineral oil. When used in infants,
the solution may be given in a nursing bottle. Pediatric doses may
also be used in dehydrated and/or debilitated adult patients. A 1:1
dilution is also recommended when the contrast medium is used in elderly
cachectic individuals.
For very
young (under 10 kg) and debilitated children the dose should be diluted:
1 part Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium
Solution) in 3 parts water is recommended.
For Enemas or Enterostomy Instillations: Gastrografin should be diluted when it is used for enemas and enterostomy
instillations. When used as an enema, the suggested dilution for adults
is 240 mL (88 g iodine) in 1,000 mL of tap water. For children under
5 years of age, a 1:5 dilution in tap water is suggested; for children
over 5 years of age, 90 mL (33 g iodine) in 500 mL of tap water is
a suitable dilution.
A usual adult dose is 240 mL of a dilute
Gastrografin solution prepared by diluting 25 mL (9.17 g iodine) to
one liter with tap water. Less dilute solutions [up to 77 mL (28.26
g iodine) diluted to one liter with tap water] may be used when indicated.
The dose is administered orally about 15 to 30 minutes prior to imaging
in order to permit the contrast medium to reach the pelvic loops.
Warnings & precautions
Do not take this medicine if: Do not administer to patients with a known
hypersensitivity to Gastrografin or any of its components.
Diagnostic procedures
which involve the use of radiopaque contrast agents should be carried
out under the direction of personnel with the prerequisite training
and with a thorough knowledge of the particular procedure to be performed.
Appropriate facilities should be available for coping with any complication
of administration, as well as for treatment of reaction to the contrast
medium .
Rectal administration
of undiluted Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium
Solution) in any patient, particularly with large doses and/or in
those with overdistention, has been reported to be associated with
mucosal irritation.
Cases of hyperthyroidism
have been reported with the use of oral contrast media. Some of these
patients reportedly had multinodular goiters which may have been responsible
for the increased hormone synthesis in response to excess iodine.
Administration of an intravascular iodinated radiopaque diagnostic
agent to a hyperthyroid patient precipitated thyroid storm; a similar
situation could follow administration of oral preparations of iodides.
Therefore, caution should be exercised when administering enteral
gastrointestinal radiopaque agents to hyperthyroid and euthyroid goiterous
patients.
Consideration should
be given to the potential for precipitation of water-soluble contrast
agents under conditions that may promote hyperacidity (i.e., fasting,
emotional upset, or stress). Harmful effects directly attributable
to precipitate formation have not been reported. However, the possibility
of interpreting the precipitate radiologically as an anatomical abnormality
(i.e., ulceration of the stomach or small intestine) or injury, should
be kept in mind. …
Diatrizoate side effects
Most adverse reactions to enteral diagnostic
radiopaque agents are mild and transitory. Nausea, vomiting and/or
diarrhea, urticaria with erythema, hypoxia, acute dyspnea, tachyarrhythmia,
and anaphylaxis have occurred following ingestion of the contrast
medium, particularly when high concentrations of large volumes of
solution are administered. Severe changes in serum osmolarity and
electrolyte concentrations may produce shock-like states . It should be kept in mind
that serious or anaphylactoid reactions that may occur with intravascular
administration of radiopaque contrast agents are theoretically possible
following administration by other routes.
About this medicine
Gastrografin (Diatrizoate Meglumine and Diatrizoate
Sodium Solution) is a palatable lemon-flavored water-soluble iodinated
radiopaque contrast medium for oral or rectal administration only.
Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate
sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and
367 mg organically bound iodine. Inactive ingredients: edetate disodium,
flavor, polysorbate 80, purified water, saccharin sodium, simethicone,
and sodium citrate.
Diatrizoate
meglumine is designated chemically as 1-deoxy-1-(methylamino)-D-glucitol
3,5-diacetamido-2,4,6-triiodo-benzoate (salt); diatrizoate sodium
is monosodium 3, 5-diacetamido-2,4,6-triiodobenzoate. Structural formulas:
How it works: The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological effects.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8c2340e4-2b42-45dc-8fac-9960e8172547. Read the full official label on DailyMed.